Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants

Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants

Objectives: The study aimed to compare the immunogenicity and safety of fractional (half) third doses of heterologous COVID-19 vaccines (AZD1222 or BNT162b2) to full doses after the two-dose CoronaVac and when boosting after three different extended intervals. Methods: At 60-<90, 90-<120, or 1...

Full description

Bibliographic Details
Main Authors: Suvimol Niyomnaitham, Anan Jongkaewwattana, Atibordee Meesing, Nawamin Pinpathomrat, Sira Nanthapisal, Nattiya Hirankarn, Sarawut Siwamogsatham, Suppachok Kirdlarp, Romanee Chaiwarith, Saranath Lawpoolsri, Supranee Phanthanawiboon, Arunee Thitithanyanont, Pokrath Hansasuta, Sansanee Chaiyaroj, Punnee Pitisuttithum
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:International Journal of Infectious Diseases
Subjects:
Immune response
COVID-19
Vaccine
Booster strategy
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971223000218

Internet

http://www.sciencedirect.com/science/article/pii/S1201971223000218

Similar Items